{"entity":{"id":"paper-erivance-vismodegib-sekulic-nejm-2012","kind":"paper","name":"ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma","aka":[],"tldr":"The hedgehog pathway inhibitor vismodegib shrank tumours in 43 percent of patients with locally advanced and 30 percent with metastatic basal cell carcinoma, becoming the first drug approved for advanced basal cell carcinoma.","summary":"Phase 2 study of 104 patients with metastatic (33) or locally advanced (71) basal cell carcinoma unsuitable for surgery or radiotherapy treated with vismodegib 150 mg daily.\n\nObjective response was 30 percent in metastatic and 43 percent in locally advanced disease (21 percent complete), with median duration of response of 7.6 months; muscle spasms, alopecia, dysgeusia and weight loss were almost universal and led many patients to stop.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2012","url":"https://doi.org/10.1056/NEJMoa1113713"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/22670903/"}],"tags":[],"related":[],"cancers":["locally-advanced-bcc"],"sections":[],"technologies":[],"targets":[],"drugs":["vismodegib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["erivance"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2012,"doi":"10.1056/NEJMoa1113713","pmid":"22670903","authors":"Sekulic A, Migden MR, Oro AE, et al.","paperType":"observational","findings":["Objective response 43 percent (locally advanced) and 30 percent (metastatic).","Median duration of response 7.6 months."],"whatItMeans":"Vismodegib (and sonidegib) is the first-line systemic treatment for locally advanced or metastatic basal cell carcinoma, often given intermittently to manage side effects.","caveats":["Single-arm; toxicity-related discontinuation is common.","Teratogenic; strict contraception required."],"changedPractice":true,"participants":104},"route":"/key-papers/paper-erivance-vismodegib-sekulic-nejm-2012/","neighbours":{"cancer":[{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/"}],"drug":[{"id":"vismodegib","kind":"drug","name":"Vismodegib","route":"/drugs/vismodegib/"}],"trial":[{"id":"erivance","kind":"trial","name":"ERIVANCE BCC","route":"/trials/erivance/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}